SpyBiotech has been spun out of University of Oxford with $5m in seed capital led by Oxford Sciences Innovation and participation from GV.
SpyBiotech, a UK-based biochemical superglue spinout of University of Oxford, launched today with £4m ($5m) of seed funding led by university venture fund Oxford Sciences Innovation.
GV, an early-stage corporate venturing subsidiary of internet technology conglomerate Alphabet, also took part in the round.
SpyBiotech hopes to use Streptococcus pyogenes, responsible for infections such as strep throat, to develop highly effective vaccines by bonding virus-like particles (VLPs) to antigens. VLPs are an established form of vaccination, but are currently…
